VTECancerWRAP: Optimizing Management of VTE in Cancer Patients

Focus on the Foundation Role of LMWH, Association Guidelines, and Long-Term Prophylaxis

HealthWRAP CME Disclosure

Please read this notice and click the acknowledgement
at the bottom of the page to continue.

Release Date:

May 30, 2009

Expiration Date:

May 30, 2011

Intended Audience:

This program is designed for all physicians, academicians, researchers, investigators, and program directors from the fields of thrombosis, oncology, and haemostasis who manage patients with thrombosis-related disorders.

Registration:

Enrollment for this HealthWRAP is complimentary, and clinicians are invited to participate in this CME-certified HealthWRAPs and/or share this invitation with other colleagues, departmental staff members, and healthcare professionals.

Grantor Support:

The following program has been supported
by an independent medical educational grant
from Eisai, Inc.

Accreditation Statement for Jointly-Sponsored Programs:

This activity has been planned and implemented in accordance with the Essentials Areas and policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of the University of Massachusetts Medical School and CMEducation Resources, LLC. The University of Massachusetts Medical School is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation Statement:

The University of Massachusetts Medical School designates this educational activity for a maximum of 2 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Disclosure:

It is the policy of the University of Massachusetts Medical School to ensure fair balance, independence, objectivity and scientific rigor in all activities. All faculty participating in CME activities sponsored by the University of Massachusetts Medical School are required to present evidence-based data, identify and reference off-label product use and disclose all relevant financial relationships with those supporting the activity or others whose products or services are discussed. Faculty disclosure will be provided in the activity materials.

Policy on Faculty Disclosure:

It is the policy of the University of Massachusetts Medical School to ensure fair balance, independence, objectivity and scientific rigor in all activities. All faculty participating in CME activities sponsored by the University of Massachusetts Medical School are required to present evidence-based data, identify and reference off-label product use and disclose all relevant financial relationships with those supporting the activity or others whose products or services are discussed. Faculty disclosure will be provided in the activity materials.

Program Faculty:

Craig M. Kessler, MD
Professor of Medicine and Pathology
Director of Division of Coagulation in the Department of Laboratory Medicine
Director of Therapeutic and Cellular Apheresis Unit
Director of the Comprehensive Hemophilia and Thrombophilia Treatment Center
Lombardi Comprehensive Cancer Center at Georgetown University Medical Center
Washington, DC

Faculty Disclosures:

Dr. Kessler discloses that he has received grant/research support from GlaxoSmithKline, consultant fees from sanofi-aventis and Eisai Pharmaceuticals, and served on speaker’s bureau for sanofi-aventis and GlaxoSmithKline

Educational Objectives:

Physicians, pharmacists, and other healthcare providers will be able to:

• Review recent trials, research, and expert analysis of issues focused on thrombosis and cancer, and apply the results and findings of these trials to clinical practice for cancer patients.
• Understand the scientific mechanisms, including the pathobiology of thrombosis-related complications, that explain the increased risk for thrombosis-related complications observed in patients with cancer.
• Learn how national guidelines for thrombosis prevention issued by ASCO, NCCN, and ACCP should impact management of patients with cancer.
• Learn specific strategies for risk-directed prophylaxis against VTE in at-risk patients with cancer.
• Learn which tumor types and therapeutic strategies place pa tients at higher risk for acquiring thrombosis-related complica tions and institute appropriate measures to reduce these risks.
• Learn how to assess and manage special needs of cancer patients at risk for VTE and how national guidelines issued by cancer-focused organizations can improve patient care in this population.
• Learn how to risk stratify patients undergoing cancer surgery, and implement guidelines recommended by 8th ACCP for pharmacologic and nonpharmacologic measures aimed at DVT prophylaxis.
• Learn how to evaluate safety and efficacy and appropriately select and employ from a range of pharmacologic options available for thrombosis management in patients with malignancy.
  

Disclaimer:

Copyright © 2009 by CMEducation Resources, LLC and Pharmatecture, LLC All rights reserved. Reproduction, distribution, or translation without express written permission is strictly prohibited.

Content on this HealthWRAP reflects the opinions, output, and analyses of experts, investigators, educators, and clinicians whose activities for, while independent, are commercially supported by the sponsor noted at the start of each activity.

Content on this HealthWRAP is not meant to be, nor substitute for national guidelines or recommendations generated by professional, academic societies, colleges, or associations.

Content on this HealthWRAP is intended for educational value only. Its contents, analyses, and any recommendation made herein are intended to make scientific information and opinion available to health professionals, to stimulate thought, and further investigation. This HealthWRAP is not designed nor is any aspect of the contents here intended to provide advice regarding medical diagnosis or treatment for any individual case. Any decisions regarding diagnosis and/or management of any individual patient or group of patients should be made on individual basis after having consulted appropriate sources, whether they be appropriate consultants and/or guidelines and recommendations issued by national organizations, professional societies, governmental health organizations, or similar bodies. This HealthWRAP is not intended for use by the layman.

Opinions expressed herein are not necessarily those of CMEducation Resources, LLC, Pharmatecture, LLC, program supporters or accreditors, but reflect the opinions and analyses of the experts who have authored the material. Mention of products or services does not constitute endorsement. Clinical, legal, financial, and other comments are offered for general guidance only; and professional counsel should be sought for all specific situations.

Copyright © 2008 All rights reserved